ACH
FDMT icon

ArrowMark Colorado Holdings’s 4D Molecular Therapeutics FDMT Stock Holding History

ArrowMark Colorado Holdings’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.7M Hold
202,864
– – 0.11% 215
2026
Q1 		$1.89M Sell
202,864
-282,525
-58% -$2.46M 0.05% 221
2025
Q4 		$3.64M Sell
485,389
-18,726
-4% -$190K 0.08% 213
2025
Q3 		$4.38M Sell
504,115
-10,499
-2% -$62.7K 0.08% 200
2025
Q2 		$1.91M Sell
514,614
-12,656
-2% -$44.5K 0.03% 231
2025
Q1 		$1.7M Sell
527,270
-267,328
-34% -$1.26M 0.03% 233
2024
Q4 		$4.43M Sell
794,598
-8,892
-1% -$69.8K 0.06% 199
2024
Q3 		$8.69M Sell
803,490
-46,711
-5% -$775K 0.11% 151
2024
Q2 		$17.8M Sell
850,201
-228,124
-21% -$5.72M 0.21% 97
2024
Q1 		$34.4M Sell
1,078,325
-123,115
-10% -$3.14M 0.39% 71
2023
Q4 		$24.3M Buy
1,201,440
+116,719
+11% +$1.54M 0.27% 91
2023
Q3 		$13.8M Buy
1,084,721
+53,323
+5% +$892K 0.17% 112
2023
Q2 		$18.6M Sell
1,031,398
-1,321
-0.1% -$24.3K 0.2% 101
2023
Q1 		$17.8M Buy
1,032,719
+50,520
+5% +$982K 0.2% 102
2022
Q4 		$21.8M Sell
982,199
-547,759
-36% -$8.46M 0.26% 88
2022
Q3 		$12.3M Buy
1,529,958
+105,644
+7% +$957K 0.15% 127
2022
Q2 		$9.94M Buy
1,424,314
+278,729
+24% +$2.71M 0.11% 161
2022
Q1 		$17.3M Buy
1,145,585
+34,006
+3% +$534K 0.15% 131
2021
Q4 		$24.4M Buy
1,111,579
+108,132
+11% +$2.65M 0.2% 111
2021
Q3 		$27.1M Sell
1,003,447
-26,450
-3% -$754K 0.21% 112
2021
Q2 		$24.8M Sell
1,029,897
-18,292
-2% -$560K 0.19% 118
2021
Q1 		$45.5M Sell
1,048,189
-15,555
-1% -$689K 0.34% 80
2020
Q4 		$44.1M Buy
+1,063,744
New +$43.9M 0.34% 84

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

ArrowMark Colorado Holdings's FDMT Position: Q2 2026 in Review

ArrowMark Colorado Holdings held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 202,864 shares worth $2.7M. The position accounts for 0.11% of the portfolio, ranked #215.

ArrowMark Colorado Holdings first reported a position in FDMT in Q4 2020 and has held it in 23 quarters since. The position peaked at $45.5M in Q1 2021. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • ArrowMark Colorado Holdings held 202,864 shares of 4D Molecular Therapeutics worth $2.7M as of Q2 2026.
  • ArrowMark Colorado Holdings left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
  • 4D Molecular Therapeutics made up 0.11% of ArrowMark Colorado Holdings's portfolio in Q2 2026, its #215 holding.
  • ArrowMark Colorado Holdings first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • ArrowMark Colorado Holdings's 4D Molecular Therapeutics position peaked at $45.5M in Q1 2021.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.